Podcasts about Merck

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with W. Kimryn Rathmell, MD, PhD, about the new and evolving ways cancer care is delivered, building networks through advocacy and more. ·       Who is Dr. W. Kimryn Rathmell?  2:17 ·       Jain and Rathmell discuss the need for physician scientists in administrative leadership. 11:37 ·       How do you think networks and communities can impact careers? 17:08 ·       What are your thoughts on using social media in the cancer space? 22:35 ·       How do you think AI is going to transform the way we deliver care? 26:21 ·       As you have navigated your career, how have you approached challenges around being a woman in leadership roles? 29:29 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Rathmell can be reached on LinkedIn. Jain reports no relevant financial disclosures. Rathmell reports a relationship with Interact Therapeutics, as well as institution relationships with Merck and Sitryx.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Interest in macrocyclic peptides (MCPs) continues to grow, which means manufacturers are facing mounting pressure to develop production methods capable of supporting commercial-scale demand of these molecules. While they offer a unique combination of potency, selectivity, and drug-like properties, the structural complexity of MCPs has historically made them difficult and costly to manufacture using traditional peptide synthesis techniques. As a result, new manufacturing approaches are emerging that aim to improve efficiency, scalability, and sustainability while expanding access to this promising class of therapeutics. In this episode of Off Script, we spoke with David Thaisrivongs, executive director, head of biocatalysis at Merck, about research recently published in Science detailing a biocatalytic manufacturing process for enlicitide, an investigational oral macrocyclic peptide designed to lower LDL cholesterol. The conversation explores the limitations of conventional solid-phase peptide synthesis, how Merck leveraged enzyme-driven manufacturing and crystallization strategies to significantly reduce process complexity, and why minimizing chromatography can be critical for commercial-scale peptide production. He also discussed the broader implications of biocatalysis for manufacturing increasingly complex therapeutic modalities and how the technology could help shape the future of pharmaceutical production.

Send us Fan MailOver the last several years, artificial intelligence has transformed from a speculative concept in healthcare into one of the most heavily funded movements in pharmaceutical and biotech history.But in 2026, the conversation is changing. The question is no longer whether AI can generate molecules, analyze pathology slides, or identify patterns in clinical data. The real question is: which of these technologies can survive the complexity of biology, regulatory scrutiny, clinical validation, and real-world deployment?Today we're joined once again by returning guest Bill Taranto, President and Founding Partner of the Merck Global Health Innovation Fund ( https://www.merckghifund.com/ ), alongside Managing Director, Dr. David Rubin, who brings a deep scientific background spanning molecular biology, oncology, precision medicine, and digital health investing.Together, Bill and David sit at a unique intersection of pharma strategy, venture investing, translational science, and clinical deployment. Through investments across AI-driven drug discovery, precision medicine, diagnostics, and digital health - including early involvement with companies like PathAI - they've had a front-row seat to what's actually working in AI-enabled healthcare…and what still breaks down when these systems encounter real-world medicine.Today we'll explore where AI is genuinely creating value across the pharmaceutical stack, why some approaches are beginning to achieve meaningful validation, what investors and pharma companies are now demanding beyond hype, and how entirely new experimental models - from organoids to AI-native biology platforms - may reshape the future of drug development.#AI #ArtificialIntelligence #DrugDiscovery #Biotech #Pharma #HealthcareAI #PrecisionMedicine #DigitalHealth #Oncology #PathAI #Roche #Biology #MachineLearning #BiotechInvesting #VentureCapital #Merck #DigitalPathology #ClinicalTrials #FutureOfMedicine #LifeSciences #AIHealthcare #MedicalInnovation #Biotechnology #CancerResearch #PrecisionOncology #Bioinformatics #HealthcareInnovation #Pharmaceuticals #MedTech #ProgressPotentialPossibilitiesSupport the show

US equity markets firmer amid yet another bout of optimism around a resolution to the US-Iran conflict, while there was also a pivot from certain technology stocks into more defensive sectors – Dow rallied +875-points or +1.73% to a record closing high of 51,561.93. UnitedHealth Group Inc rose +5.16% to be the leading Dow component, with analysts at Bank of America upgrading their recommendation in the health insurer to ‘Buy' and lifting their price target to US$450 (from US$420 previously), citing expectations of improving margins as a result of more favourable medical cost trends. Goldman Sachs Group Inc (+4.96%) and Merck & Co Inc (+4.85%) also gained ~5%.

In this episode of the HR Leaders Podcast, we sit down with Khadija Ben Hammada, Member of the Executive Board and Chief People Officer at Merck Group, to unpack how HR can lead through AI transformation without losing the human heart of the organization.Khadija shares why leaders cannot run global organizations from an ivory tower, and why being close to employees on the ground creates the trust, safety, and pride people need to speak up. She explains how field visits, human connection, and a strong sense of global community help Merck stay united across regions, even as the world outside becomes more fragmented.Most importantly, she breaks down how Merck is building AI capability across the business, from AI literacy for everyone, to leader upskilling, internal AI tools, hackathons, flagship use cases, and HR agents that can improve employee experience at scale. Through it all, Khadija is clear: AI should take tasks, not humanity, and HR must stay at the intersection of business, technology, and empathy.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

Dubai wirkt wieder normal, doch unser Gast im Heiko Thieme Club, Carsten Stork, widerspricht dem bequemen Bild der schnellen Beruhigung: Der Waffenstillstand im Nahen Osten sei fragil, die Unsicherheit bleibe real. Für Rohstoffe heißt das: Öl findet zwar Wege an der Straße von Hormus vorbei, doch Stork hält eine neue Eskalation und Ölpreise von 120 bis 130 USD für möglich. Gold bremsen dagegen die Zinserwartungen, auch wenn Zentralbanken weiter stark kaufen. Sein Favorit bleibt Kupfer: Ohne Kupfer keine Rechenzentren, keine KI-Infrastruktur, keine Elektrifizierung. Wirtschaftlich sei Kupfer auf Sicht von zehn bis 15 Jahren wichtiger als Gold. Heiko Thieme ordnet das in seine Marktsicht ein: Hohe Ölpreise könnten Börsen kurzfristig drücken, der langfristige Aufwärtstrend bleibe aber intakt. Bei heißen IPOs wie SpaceX, OpenAI oder Anthropic rät er zur Geduld: Neuemissionen meiden und später mit Abschlag prüfen. Bei Oracle empfiehlt Thieme, Teilgewinne mitzunehmen und den Rest abzusichern. In der DAX-Runde sieht Thieme Merck als Halteposition, MTU als Kauf in Tranchen, Münchener Rück als Qualitätstitel, Porsche Automobil ohne Priorität und Qiagen vorsichtig dosiert. Direkter Link zum Heiko Thieme Club, link zum Beitrag: https://go.brn-ag.de/527

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

"I've seen death in the face numerous times. I. I am going to do something going forward that is going to help people in a big way. And so I am. I am. I'm doing it." ~Ksenia MerckKsenia Merck joins the show to share her powerful story of love, loss, caregiving, creativity, and renewal. After caring for her elderly mother until her passing and then losing her beloved husband Bill to cancer, Ksenia Merck found herself navigating profound compound grief and the search for healing. Through her journey, she discovered the transformative power of creativity and art.Listeners will be deeply moved by Ksenia Merck's reflections on “re-lifing” herself. She shares her experience of illustrating and publishing Bill's unfinished novel "Ghost Flower," and her ongoing mission to build community and help others on the widowhood journey. This episode is full of wisdom, hope, and encouragement for anyone grieving or seeking new purpose after loss.Key takeaways:The traumatic experience of Bill's sudden illness, ICU stays, and the couple's recognition of shared PTSDThe inspiration and healing that came from illustrating and publishing "Ghost Flower," Bill's final unfinished manuscriptFinding comfort and connection through creativity, especially in times of griefThe significance of honoring one's own grief timeline and resisting outside pressure to “move on”Recognizing and appreciating signs from loved ones after their passing, especially through natureTrust yourself and your intuition to make the choices that feel right for you on your widowhood journey! You know what's best for YOU!You can find Ksenia and her book Ghost Flower at https://www.merckiipress.com/ksenia-merckStruggling with an identity crisis? Many widows find themselves wondering "Who Am I Now?" Get the latest workbook in the Widow 180 Workbook series, The Who Am I Now? Workbook at www.widow180.com/whoaminow  Be sure to join our Facebook group, Widow 180 The Community: https://www.facebook.com/groups/312036956454927Also follow us on Insta: https://www.instagram.com/widow_180/Check us out on YouTube at Widow 180: The Channel: https://www.youtube.com/channel/UC-DK_dl31qMilJ5cE6t9MVQFor more blog posts and resources go to www.widow180.comQuestions? Email me at jen@widow180.com

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.    Episode Timestamps:  00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.  00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.  00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.  00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.  00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.  00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.  00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.  00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit    Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray;  LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/    Keep up with David Radwaner;  LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/    Keep up with Tom Brockbank;  LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/      Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

──────────────────────────────────────── [00:04:09] Operation Warp Speed Killed More Americans Than Any Other War — Trump Calls Himself the Father of the Vaccine VAERS shows COVID shots produced more deaths and injuries than all other FDA-approved vaccines combined. Trump forced FDA approval and still boasts. Johnson blames Biden's FDA, not Trump. ──────────────────────────────────────── [00:15:25] Ron Johnson: Biggest Government Scandal of My Lifetime — FDA Knew It Was Hiding the Safety Signals FDA's vaccine division head was briefed their algorithm would mask signals — 26 days later hiding 60 signals including sudden cardiac death and stroke types. Johnson refuses to name Trump. ──────────────────────────────────────── [00:24:39] Trump's EPA Reversed the Fluoride Ruling by Banning All Scientific Evidence Produced After 2020 The Ninth Circuit sent the case back with instructions to exclude all evidence from the last six years. Lee Zeldin is also pushing to keep PFAS forever chemicals in the water. ──────────────────────────────────────── [00:32:57] Merck Is Lobbying to Give HPV Vaccines to Infants — Sales Are Down 40% Globally HPV is sexually transmitted — a four-year-old cannot be exposed to it. Merck hired former Gates Foundation advisors who declared no conflicts of interest. Childhood vaccine classification means zero liability. ──────────────────────────────────────── [00:43:48] Josh Shapiro: Tracking AIPAC's Money Is Racist — They Can Buy Congress, You Are Not Allowed to Watch Pennsylvania's governor said AIPAC tracking is intimidation. Knight: they're calling for speech to be criminalized. AIPAC doesn't register as a foreign agent — you can't look at who they're buying. ──────────────────────────────────────── [00:51:48] Todd Blanche's Background: Fake Mossad Agent, Twin Grifters, Forgery and Malpractice Accusations Before representing Trump, Blanche's clients used a fake Mossad agent to threaten witnesses and bribe DOJ officials. The case ended with forgery and malpractice accusations against Blanche. ──────────────────────────────────────── [01:15:23] Blanche Is Setting Up the Ghislaine Maxwell Pardon — After a Long Interview, She Was Moved to Club Fed Blanche visited Maxwell for a long interview; shortly after she was moved to comfortable quarters. He pushed prosecution of political enemies and declined to investigate those tight with Epstein. ──────────────────────────────────────── [01:21:24] The Trump Phone Is Finally Shipping — It's an HTC Running on American Values, Assembled in a Box After months of broken promises and removing buyer protections, Trump Mobile is shipping. CNET found the processor identical to a Taiwanese HTC. Designed with American values in mind. ──────────────────────────────────────── [01:41:44] SWAT Team Destroyed a Texas Woman's Home — Government Said She Wasn't a Victim — Six Years Later She May Get $60,000 Police were given the key, garage opener, and gate code — drove a Bearcat through the fence, blew up the garage, drove through the front door. Government argued she wasn't a victim. ──────────────────────────────────────── [01:50:06] Texas Woman Arrested Under a Bomb Threat Law for Posting That Her Town's Water Was Brown The police chief applied a felony false alarm statute — designed for fake bomb threats — to a woman warning neighbors about brown water. The city later admitted the water was undrinkable. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

──────────────────────────────────────── [00:04:09] Operation Warp Speed Killed More Americans Than Any Other War — Trump Calls Himself the Father of the Vaccine VAERS shows COVID shots produced more deaths and injuries than all other FDA-approved vaccines combined. Trump forced FDA approval and still boasts. Johnson blames Biden's FDA, not Trump. ──────────────────────────────────────── [00:15:25] Ron Johnson: Biggest Government Scandal of My Lifetime — FDA Knew It Was Hiding the Safety Signals FDA's vaccine division head was briefed their algorithm would mask signals — 26 days later hiding 60 signals including sudden cardiac death and stroke types. Johnson refuses to name Trump. ──────────────────────────────────────── [00:24:39] Trump's EPA Reversed the Fluoride Ruling by Banning All Scientific Evidence Produced After 2020 The Ninth Circuit sent the case back with instructions to exclude all evidence from the last six years. Lee Zeldin is also pushing to keep PFAS forever chemicals in the water. ──────────────────────────────────────── [00:32:57] Merck Is Lobbying to Give HPV Vaccines to Infants — Sales Are Down 40% Globally HPV is sexually transmitted — a four-year-old cannot be exposed to it. Merck hired former Gates Foundation advisors who declared no conflicts of interest. Childhood vaccine classification means zero liability. ──────────────────────────────────────── [00:43:48] Josh Shapiro: Tracking AIPAC's Money Is Racist — They Can Buy Congress, You Are Not Allowed to Watch Pennsylvania's governor said AIPAC tracking is intimidation. Knight: they're calling for speech to be criminalized. AIPAC doesn't register as a foreign agent — you can't look at who they're buying. ──────────────────────────────────────── [00:51:48] Todd Blanche's Background: Fake Mossad Agent, Twin Grifters, Forgery and Malpractice Accusations Before representing Trump, Blanche's clients used a fake Mossad agent to threaten witnesses and bribe DOJ officials. The case ended with forgery and malpractice accusations against Blanche. ──────────────────────────────────────── [01:15:23] Blanche Is Setting Up the Ghislaine Maxwell Pardon — After a Long Interview, She Was Moved to Club Fed Blanche visited Maxwell for a long interview; shortly after she was moved to comfortable quarters. He pushed prosecution of political enemies and declined to investigate those tight with Epstein. ──────────────────────────────────────── [01:21:24] The Trump Phone Is Finally Shipping — It's an HTC Running on American Values, Assembled in a Box After months of broken promises and removing buyer protections, Trump Mobile is shipping. CNET found the processor identical to a Taiwanese HTC. Designed with American values in mind. ──────────────────────────────────────── [01:41:44] SWAT Team Destroyed a Texas Woman's Home — Government Said She Wasn't a Victim — Six Years Later She May Get $60,000 Police were given the key, garage opener, and gate code — drove a Bearcat through the fence, blew up the garage, drove through the front door. Government argued she wasn't a victim. ──────────────────────────────────────── [01:50:06] Texas Woman Arrested Under a Bomb Threat Law for Posting That Her Town's Water Was Brown The police chief applied a felony false alarm statute — designed for fake bomb threats — to a woman warning neighbors about brown water. The city later admitted the water was undrinkable. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In this episode of Retail War Games, I am joined by Jim Umlauf, the founder of 4Knines. Jim is a fascinating operator who spent 20 years at the pharmaceutical giant Merck before pulling the ripcord to turn a weekend-warrior side hustle into a highly efficient, multi-million-dollar pet brand. We explore how Jim completely re-engineered traditional direct-to-consumer operations by shrinking his internal team down to just three full-time people and leveraging heavy intellectual property, including well over 20 patents. But the most mind-blowing part of this episode is how Jim is completely ahead of the curve on AI-driven shopping. He reveals how 4Knines is already generating nearly 10% of its entire revenue directly through large language models like ChatGPT and Perplexity as consumers shift from search engines to AI purchase agents. We also talk about his high-profile contract deals with auto giants like Ford and Mopar, and how to protect profit margins against volatile tariffs.  

What started as a revolutionary treatment for river blindness became something far messier. Listen to Drug Story wherever you get your podcasts! Subscribe to SiriusXM Podcasts+ to listen to new episodes of 99% Invisible ad-free and a whole week early. Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“You can't manage other people unless you manage yourself first.” — Peter DruckerWhat if the biggest thing holding people back in their careers…is that they don't even know the real game being played?In this episode, Jay sits down with Booker Farrior—former enterprise operator, executive coach, systems thinker, and founder of Coaching By The Book.With experience leading inside organizations like Vanguard, Merck & Co., and Bristol Myers Squibb, Booker brings a rare perspective that blends leadership, behavioral science, systems thinking, and career strategy.This conversation is a masterclass in modern leadership, career ownership, and understanding how organizations actuallywork.Inside this episode:Why every professional should think like a companyWhat it means to truly become the CEO of your own careerThe difference between “doing your job” and strategically managing your trajectoryWhy many employees are unknowingly playing the wrong game inside organizationsThe hidden “second scorecard” that determines promotions, opportunities, and influenceHow reputation quietly shapes careers more than most people realizeWhy self-awareness is becoming one of the most important leadership skills in the modern workplaceHow organizations unintentionally disable growth—even while saying they support itWhy attention spans, side hustles, and disengagement are changing company culture foreverBooker also breaks down one of the most practical frameworks shared on the podcast yet:Antecedent → Behavior → ConsequenceA simple but powerful model for understanding feedback, behavior change, leadership, and culture. One of the biggest takeaways from this episode:There are two scorecards in every organization.The first measures your output, KPIs, and deliverables.The second measures how people experience you, perceive you, trust you, and advocate for you when you are not in the room.Most people only know the first scorecard exists. This episode is for:Leaders trying to develop people more effectivelyProfessionals who feel stuck despite producing resultsEntrepreneurs building teamsAnyone who wants to better understand influence, growth, and modern workplace dynamicsBecause career growth is not just about working harder.It's about understanding how value, perception, relationships, and leadership actually operate in the real world.And once you understand that…everything changes.

Meet Ksenia J. Merck. For decades, she's been an esteemed architect, mastering the art of physical structure in large-scale airport design. But Ksenia is also a profound artist and creative storyteller, whose latest project transcends the blueprints of the material world. After experiencing deep personal loss, Ksenia channeled her grief into a mission: posthumously publishing and illustrating her late husband's science fiction novel, Ghost Flower. This isn't just a tale of time travel, aliens, and saving humanity in 2035—it's a testament to a love that transcends time and a powerful tool for healing. Discover how Ksenia used art to navigate her grief journey, find a new purpose, and bring this inspiring, genre-blending story to life.Love the show? Subscribe, rate, review, and share!Here's How »Join the On Your Mind Community today:journeysdream.orgTwitterInstagramFacebookYouTube

Generative AI and other technologies are transforming clinical research and trials. Find out how it's done.     The clinical trials sector is risk-averse, heavily regulated, and not often thought of as a technology first-mover. How is Merck changing that perception by using AI to improve insights, innovation, and operations?     Join Steve Odland and guest Jennifer Sheller, senior vice president and head of global clinical trial operations at Merck, to find out how the company is using AI for clinical research and clinical trials, why "human in the loop" remains essential, and how Merck thinks about the ethical, safety, and privacy considerations of digital health.     For more from The Conference Board:  How AI Can Help Remedy the US Health Care Workforce Crisis  Health Care Workforce Policy Summit: Insight Summary  Navigating the Health Care Landscape in 2026 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

Jordan Sather and Nate Prince dig into a week that felt like a nature documentary gone wrong. Ticks are surging across the Northeast and Midwest, alpha gal syndrome is quietly making red meat allergies a real and growing problem, and a peer reviewed bioethics paper from Western Michigan University actually argues scientists are morally obligated to gene-edit lone star ticks to spread alpha gal and push people away from meat. No, that is not satire. Meanwhile, the WHO and media are still flogging hantavirus and Ebola, and the Trump administration is still not biting. PFAS contamination sits in over 95% of Americans' bloodstreams, and Jordan breaks down where it comes from and how zeolite may help pull it out. RFK scores the largest autism fraud bust in US history, Dr. Oz keeps hammering Medicare and hospice fraud, and TrumpRx quietly adds 600 more generic drugs. Big pharma is apparently starting to sweat, with mass layoffs hitting Pfizer, Merck, Novo Nordisk, and more.

How can we move from fearing equity to championing it?    In this episode of Women of Color Rise, I speak with Celeste Warren, former Vice President and Chief Diversity and Inclusion Officer at Merck and author of The Truth About Equity. With nearly three decades of experience, Celeste has been recognized by Black Enterprise's "Top Executives in Global Diversity and Inclusion."   Celeste's father was the first black teacher and principal in western Pennsylvania. She shares how her "dinner table lessons" taught her that while obstacles are real, they are never an excuse to stop succeeding. She opens up about the internal struggle of stepping into a DEI role as a woman of color and how she learned to stop "putting her blackness to the back." She shares powerful lessons for rising leaders: The Rocks and the Fence. Equity isn't about taking things away; it's about providing the "rocks" needed to see over systemic fences while we work to tear those fences down. Boil Your Own Pot. You don't have to save the world alone. Impact starts by influencing the two or three people immediately around you. Growth vs. Fixed Mindset. View opportunity as a bar graph that can rise infinitely, rather than a finite pie where one person's gain is another's loss. Embrace Your "Lock and Load" Energy. Learn to balance your drive with a "servant leadership" heart that nurtures and protects your team.   Celeste's journey to global DEI leader is a wonderful model of authenticity and intentionality.   Get full show notes and more information here:  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest happenings shaping the landscape of this dynamic industry. The pharmaceutical and biotech sectors are navigating a complex landscape replete with scientific advancements and regulatory challenges. A significant legal development comes from Takeda, which faces an $885 million verdict in a landmark pay-for-delay antitrust case. This ruling highlights the intense scrutiny of pharmaceutical companies over antitrust regulations, with potential implications for drug pricing strategies and industry practices. The possibility of tripling damages under these laws could set a precedent affecting future business operations, as Takeda plans to appeal, underscoring the high stakes involved in such litigation. Meanwhile, on the regulatory front, the White House's decision to include 600 generic medications in the TrumpRx purchasing portal marks a strategic effort to improve drug affordability. While its overall impact remains uncertain, this initiative aims to bridge gaps in medication accessibility for cost-sensitive populations. Similarly, Roche's licensing agreement with the Medicines Patent Pool to allow generic versions of Xofluza in 129 developing countries is a noteworthy step towards enhancing global access to essential medicines. These efforts underscore ongoing attempts to address affordability and accessibility concerns on a global scale. In clinical developments, UCB's Bimzelx has shown promising results against AbbVie's Skyrizi in treating psoriatic arthritis, demonstrating a statistically significant reduction in disease activity compared to Skyrizi in a Phase 3b trial. With nearly half of the patients showing improved outcomes at week 16, Bimzelx is poised to become a competitive therapeutic option, potentially redefining treatment protocols for psoriatic arthritis. Novartis's termination of its contract with Chinese CDMO Porton Pharma Solutions due to regulatory issues underscores the challenges inherent in cross-border pharmaceutical partnerships. The $64 million legal claims looming over this decision highlight the financial and operational risks associated with international collaborations. Meanwhile, biopharmaceutical buyers are increasingly turning to artificial intelligence and local expertise to navigate rising licensing costs in China. Sanofi and Wave Life Sciences are making progress in addressing α1-antitrypsin deficiency (AATD), a genetic disorder that has witnessed limited therapeutic innovation for decades. Their efforts were highlighted at the American Thoracic Society meeting, showcasing ongoing attempts to bridge treatment gaps for rare diseases through next-generation approaches. Strategic investments continue to shape the industry, as evidenced by Lauxera Capital Partners' successful EUR520 million fundraising aimed at advancing healthcare technologies. Additionally, Merck's agreement to supply Keytruda for Exelixis' colorectal cancer trial exemplifies collaborative efforts crucial for advancing cancer research. These developments reflect an industry balancing innovation with regulatory compliance and market dynamics. Scientific progress is also evident in Relay Therapeutics' advancement with its PI3K inhibitor, which has shown promising Phase 2 data in treating blood vessel disorders. This underscores the potential of PI3K inhibitors to address unmet medical needs by targeting pathways significant in cancer and other diseases. The integration of artificial intelligence into drug discovery processes is another critical trend. Incyte's collaboration with Edison Scientific aims to enhance decision-making and streamline drug discovery, showcasing AI's potential to revolutionize R&D efficiency. However, persistent challenges remain as AI scales up but doesn't yet resolve clinical trial protocol issues fully. On the business front, Bristol Myers Squibb considers investing $1 billion in a Houston manufacturing plant, emphasizing strategic infrastructure investments crucial for meeting growing pharmaceutical demands. In drug approvals, AstraZeneca's Baxfendy has received FDA approval for treating uncontrolled hypertension by targeting aldosterone synthesis—offering a novel approach as a combination therapy. Moreover, Merck & Co.'s sacituzumab tirumotecan has achieved Phase 3 success in endometrial cancer trials, demonstrating superior survival outcomes compared to chemotherapy. This highlights the growing impact of targeted therapies in oncology and the ongoing shift towards precision medicine. Despite these positive developments, challenges persist. BioMarin Pharmaceutical's BMN 401 faced setbacks after missing key Phase 3 endpoints for skeletal healing in ENPP1 deficiency patients—highlighting complexities in rare disease drug development. In conclusion, these diverse developments reflect an industry steadfastly committed to advancing healthcare through scientific innovation while navigating regulatory hurdles and operational challenges. As these sectors evolve further, maintaining a balance between rapid innovation and rigorous oversight remains essential to ensuring impactful treatments reach patients worldwide promptly. Thank you for tuning in to Pharma Daily—stay informed and stay ahead of industry trends with us tomorrow!Support the show

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency's two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary's tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would take the role. For now, FDA Deputy Commissioner for Food Kyle Diamantas is in charge.Eli Lilly's David Ricks was the highest paid pharma CEO last year, but J&J's Joaquín Duato made the most relative to rank-and-file employees, with a median pay ratio of 358 to one. He was on the top of BioSpace's list last year, too, with a ratio of 293 to 1. Last month, Revolution Medicines' RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. This week, Truist Securities went so far as to nominate RevMed as “the next oncology titan,” a title currently held by Merck and its blockbuster cancer drug Keytruda. Safety continues to challenge the gene therapy space, especially in Duchenne muscular dystrophy. Late last week, REGENXBIO announced mixed results from a Phase 3 program—the gene therapy did lead to functional improvements, but two serious adverse events caused the stock to drop 37%.Finally, Amgen's rare disease drug Tavneos continues to face scrutiny. Last month, the FDA alleged that doctored data were filed to support Tavneos' initial approval. Now, it's been linked to 20 deaths in Japan.

This week on Conflict Managed we welcome Shalin Desai. Together we explore: Trying to escape vs. learning the skills to navigate difficult situations Learning and practicing The Art of Living breathing What is within our control Training your mind The role of emotions at work The connection between breath and emotions Emotional regulation: how? Taking the mental “trash” out regularly Conflict Managed is available wherever you get your podcasts and on YouTube @3pconflictrestoration   Shalin Desai is the Director of Programs for the Art of Living Foundation, one of the world's largest nonprofit organizations, whose initiatives have positively impacted over 500 million people across 180+ countries. With more than 25 years of experience teaching breathwork and meditation, Shalin is known for integrating ancient wisdom with modern leadership and well-being practices. He also serves as Chief Revenue Officer of Sri Sri Tattva, a global wellness brand offering natural and Ayurvedic products that promote holistic health through a blend of tradition and science. For over 15 years, Shalin has designed and delivered corporate leadership and wellness programs for organizations including Microsoft, Dell, Boston Consulting Group, Accenture, Salesforce, Eli Lilly and Company, and Merck & Co. His work helps leaders and teams manage stress, build resilience, and cultivate mental clarity while reconnecting with a deeper sense of purpose. Shalin is known for his Intuitive Life Scan, a breakthrough approach in which trained guides provide unbiased insights into an individual's current situation. A highly engaging speaker known for his relatable storytelling and humor, Shalin inspires audiences with practical techniques they can apply immediately to improve focus, leadership, and overall well-being. Shalin holds a degree in Supply Chain Management from the State University of New York and lives in Indianapolis with his wife and two children. Conflict Managed is produced by Third Party Workplace Conflict Restoration Services and hosted by Merry Brown.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

Josh's guests: Karen Masterson Koch, founder, Aloe Life aloe vera. How we can use aloe vera for beautiful skin and improved digestion, what to look for in a quality aloe vera supplement Cheryl Hines - actor, Curb Your Enthusiasm, with Larry David Cheryl has a new memoir Unscripted, learn how to defend yourself against an emu and a yak Peter C. Gotzsche - author, How Merck and Drug Regulators Hid Serious Harms of the HPV Vaccines Merck has committed scientific misconduct before, the fraud related to Merck's arthritis drug, VIOXX, which killed tens of thousands of patients because Merck concealed that it causes heart attacks find us at: www.HeresToYourHealthWithJoshuaLane.com  

Cut through the hype of Multi-Cancer Early Detection (MCED) tests and learn how to counsel patients on the real-world utility, false-positive risks, and the "stage shift" debate of these emerging blood assays. We are joined by world-renowned oncologist Dr. Margaret Tempero,UCSF Cancer Early Detection and Interception, to discuss whether these tests are truly ready for clinical prime time.Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMEShow Segments 00:00 Introduction  01:57 Current Cancer Screening Programs  06:05 Emerging Blood-Based Cancer Tests  11:55 Test Characteristics and Limitations  18:05 Practical Considerations for Patients  25:33 Direct-to-Consumer Testing/Whole Body MRIs 36:46 Navigating Positive Test Results  45:10 Anxiety and Patient Education  47:08 Future Directions in Cancer Screening  Outro Credits Producer, Writer, Show Notes, Infographic, Cover Art: Molly Heublein MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Margaret Tempero, MD DisclosuresDr. Tempero reports the following financial relationships: Grail (research support), Global Bio Access Fund (Advisor), Bristol Myers Squibb (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Astra Zeneca (Membership on Advisory Committees or Review Panels, Board Membership, etc), Immunovia (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Merck (advisory committee), Renovo Rx (advisory committee), Urogen (Advisor). Financial relationships have not ended. The Curbsiders report no relevant financial disclosures. Sponsor: FIGS Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.  Sponsor: FreedTry Freed Front Desk free for 7 days at getfreed.ai/front-desk.Sponsor: Quince Go to Quince.com/curb for free shipping on your order  and 365-day returns. Now available in Canada, too. 

Dr. Todd Bilby leads the U.S. dairy technical services team at Merck Animal Health. His areas of expertise includes dairy reproduction, cow comfort and transition management, all grounded in his university research and extension background. In this episode of DairyVoice, host Connie Kuber of Sealpro Silage Barrier Films talks with Dr. Bilby about the evolution of dairy reproduction over the years. Dr. Bilby discusses Targeted Reproductive Management (TRM), which is based on the idea that when a producer uses monitoring technology, they can take advantage of those cows that show a strong natural heat. He explains how dairy producers can utilize both the advantages of monitoring technology and the great results they can achieve with synchronization.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

In 1976, Merck's CEO told Fortune magazine his dream was to make drugs for healthy people and sell them to everyone. Fifty years later, that dream is the air we breathe.In this solo episode, Dr. Roger McFillin traces how a generation was taught that being human is a disease. He walks through the 1994 inflection point, the Zoloft commercial that rewrote a culture, the academics and journals and sales reps who built the influence machine, and the school-to-pediatrician-to-customer-for-life pipeline that captured childhood itself.He reflects on the recent HHS mental health summit, what it gets right, and what the bureaucrats are still unwilling to say out loud. He names what was lost in the trade. The wisdom passed down through generations. The understanding that emotions are a guidance system, not a malfunction.The mental health industrial complex is not a healthcare system. It's a control system. The drugs are weapons. The diagnoses are chains.This is how you walk out of the cage.

This episode covers: Cardiology This Week: A concise summary of recent studies Biomarkers in heart failure Digoxin in HFrEF Scientific Highlights from Heart Failure 2026 Host: Wilfried Mullens Guests: Lynne Stevenson, Dirk van Veldhuisen, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/2565 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. A ny views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Dirk van Veldhuisen and Lynne Warner Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report:Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Theresa McDonagh has declared to have potential conflicts of interest to report: honoraria from Boeringer Ingelheim. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

US President Trump said they are only going to make a good deal regarding Iran and will have a long talk with Chinese President Xi about the Iran war.Iran will not enter the second round of talks with the US without fulfilling five confidence-building conditions, local media reported.US President Trump posted that NVIDIA CEO Huang is on Air Force One along with a number of CEOs of large US companies.UK government whips believe Wes Streeting will make his move on Thursday to avoid clashing with the King's Speech.APAC stocks traded mixed; European equity futures indicate a positive cash market open with Euro Stoxx 50 futures up 0.8%.Looking ahead, highlights include Swedish Inflation Final (Apr), French Inflation Final (Apr), EZ Employment Change (Q1), Industrial Production (Mar), GDP 2nd Estimate (Q1), US PPI (Apr), BoC Minutes (Apr), Riksbank Minutes (May), IEA OMR (May), OPEC MOMR (May). Speakers include BoE's Mann, Fed's Collins & Kashkari, ECB's Lane & Lagarde. Supply from Australia, Italy, Germany & US. Earnings from Cisco Systems, Alibaba, Siemens, Deutsche Telekom, Allianz, E.ON, Merck & RWE.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Nos centramos hoy en ABN Amro, Allianz, Merck, Infineon... Con Alberto Roldán, profesor de Finanzas de la Universidad Europea

Table of Contents: Genetic RNA “vaccines” are now being used in livestock across the U.S., Canada, Chile, Mexico, and the Philippines. Merck’s gene-based shots (SEQUIVITY) have been injected into MILLIONS of pigs across the globe since 2012 — and almost NO ONE knows! Moderna’s new FDA approved COVID injection mNEXSPIKE literally means VIOLENT DEATH in Latin–FDA approval despite ZERO placebo tests & SERIOUS adverse events of MYOCARDITIS & CANCER–“ALL COVID Vaccines should be PULLED from the market IMMEDIATELY.”~Dr Jeff Barke, MD THREE U.S. states have introduced legislation designating COVID-19 mRNA injections as BIOLOGICAL WEAPONS OF MASS DESTRUCTION Scott Johnson's 6 Part Teaching: Pharmakeia: Sorcery, Pharmaceuticals & the Roots of Modern Day Drug-Parts 1-6–September 21, 2008 Is There A 700% Food Price Increase Coming? ‘Megadrought Is HERE’: We Just Experienced the DRIEST First Three Months of a Year in US History “No Quick Fixes”: Prepare for Energy Rationing, Mandatory Water Restrictions, Higher Beef Prices Farmers are sounding the alarm and few are listening–American farmer, Julius Ray Tucker, just tested his soil & found 5X more aluminum than last year–His GMO seeds grow perfectly, but his heirloom crops are dying! — Meanwhile, Bill Gates is pushing GMO seeds engineered to thrive in aluminum-rich soil and geoengineering delivering that aluminum from our skies! Trump's Federal government using clever trick to force AI data centers on unsuspecting local communities–Trump executive order being used to override public opposition and local ordinances that forbid construction of massive AI data-collection centers that will power the coming 24/7 surveillance state! The LARGEST “hyperscale” data center in the world is being proposed in Box Elder County, Utah. It’s approx. 40,000 acres/62 square miles, backed by Canadian millionaire Kevin O'Leary. Fast-tracked by Utah's Military Installation Development Authority, backed by Gov. Spencer Cox, with the public locked out of the decision process. Utah, say hello to a 50% increase in CO₂ emissions, polluted water, and 24/7 noise and light pollution. Foreclosures Sweep Across America! Hundreds Of Thousands Of Families Have and Will Lose Their Homes Texas Governor Hands State Over To India Socialist Muslim Devil New York City Mayor Mamdani LEGALIZES Shoplifting… Wiping 8,400 Businesses OFF THE MAP Mayor Mamdani LEGALIZES Squatting… as NYC’s Largest Landlord ABANDONS 6,000 Apartments PDF: Emergency Freedom Alerts 5-11-26 Click Here To Play The Part 2 Audio Source

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories and trends shaping the industry. Daiichi Sankyo has unveiled a bold five-year business plan with an eye on rising to become a top-five global oncology leader by 2035. This ambition is driven by a $1.3 billion initiative focused on antibody-drug conjugates, or ADCs, which are targeted cancer therapies. These plans highlight a strategic emphasis on oncology and operational efficiencies designed to maintain competitive advantage in a rapidly evolving market. Meanwhile, CSL Limited faces a more challenging landscape, adjusting its revenue projections and facing a significant impairment related to its acquisition of Vifor Pharma. These financial challenges underline the risks inherent in large-scale acquisitions within the pharmaceutical sector, necessitating a reassessment of strategic priorities and investments in R&D. Regulatory developments continue to be pivotal, with Partner Therapeutics' bispecific antibody Bizengri gaining FDA national priority designation for rare bile duct cancer. This underscores the FDA's dedication to expediting critical therapies through its National Priority Pilot program, aiming to bring life-saving treatments to underserved populations quickly. However, regulatory uncertainty looms with President Donald Trump's reported plan to dismiss FDA Commissioner Marty Makary, which could impact the agency's leadership and agenda. Additionally, a Supreme Court ruling has temporarily reinstated telemedicine access to mifepristone, an abortion pill, spotlighting the ongoing debates about reproductive healthcare accessibility through telemedicine. In research news, Novo Nordisk's collaboration with an AI biotech firm marks a strategic shift aimed at rescuing its Parkinson's cell therapy program. This partnership highlights the increasing role of artificial intelligence in drug development, particularly for revitalizing stalled projects using advanced technological applications. On the clinical trial front, Inhibrx's midphase results are promising for their OX40 agonist combined with Merck's Keytruda, showing doubled response rates in cancer patients. Such advancements underscore the potential of combination therapies in oncology and are likely to draw more investment interest from major players like Merck. Amgen's investment in a quantum technology firm poised for an IPO represents another exciting frontier. The application of quantum computing in drug discovery could revolutionize computational biology by accelerating therapeutic discoveries and improving precision medicine approaches. The biotech sector is also seeing financial maneuvers with quantum tech firms planning IPOs following investments from companies like Amgen. This signals a growing interest in leveraging quantum technology for breakthroughs in drug discovery. In Alzheimer's research, a novel gene therapy study presents an innovative method for clearing amyloid plaques from mouse brains without crossing the blood-brain barrier. By sending a protective gene to the liver, researchers achieved systemic plaque clearance—an approach that could revolutionize treatment strategies if successful in human trials. A new development in diagnostics involves a blood test predicting patient responses to GLP-1 receptor agonists like Ozempic and Wegovy. As these drugs become popular for weight management, such diagnostics could optimize outcomes by identifying patients most likely to benefit. Omada Health reported a 42% revenue increase in Q1, reflecting the expanding digital health solutions market. Their collaboration with Eli Lilly's employer weight loss program indicates rising demand for comprehensive health strategies integrating pharmacotherapy and digital health platforms. Overall, thSupport the show

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs. Wyatt explains Infinimmune's 'discovered in humans' antibody discovery platform, how the company was launched and initially funded, and how Infinimmune landed a Merck collaboration worth up to $838 million. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

From practical risk stratification to the real-world challenges of delivering BCG, Dr. Aly-Khan Lalani and Dr. Christopher Wallis lead a conversation with Dr. Kulkarni about non-muscle invasive bladder cancer and its rapidly evolving treatment landscape. Dr. Kulkarni is a urologic surgeon at the Princess Margaret Cancer Centre, University Health Network, and a surgeon-scientist and Assistant Professor at the University of Toronto. As a thought leader in bladder cancer, he shares key clinical decision points, patient-centred considerations, and practical strategies that clinicians can apply today.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

In Part 2 of the Bladder Cancer Awareness Month series, Dr. Kulkarni, Dr. Lalani and Dr. Wallis examine a "systemic therapy first" approach. Using a real-world patient scenario, the doctors break down the latest clinical trial data and discuss how the surge in neoadjuvant therapy is reshaping everyday decision-making.The conversation also tackles the unique challenges of Upper Tract Urothelial Carcinoma. From evidence gaps in upper tract care to the complexities of trial design, this episode offers a forward-looking map of the evolving urothelial cancer landscape.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Bonus Episode for May 8. Financial results from pharmaceutical companies Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb and AbbVie show strong demand continuing for weight-loss drugs and autoimmune treatments. Wall Street Journal pharma reporter Peter Loftus discusses which drugmakers have the upper hand in the race to dominate those markets.  WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Lindsay Jurist-Rosner, Co-Founder and CEO of Wellthy, and Stephan Dolling, AVP of Global Benefits & Well-being at Merck, joined us on The Modern People Leader. We talked about the rising pressures facing working families and what companies can do to support their employees that are caregivers.----  Sponsor Links:

Today Lisa continues her conversation with Michael Gelb, the world's leading authority on the application of genius thinking to personal and organizational development. He is a pioneer in the fields of creative thinking, accelerated learning, and innovative leadership. Michael leads seminars for organizations such as DuPont, Merck, Microsoft, and Nike. He brings more than 30 years of experience as a professional speaker, seminar leader and organizational consultant to his international clientele. Listen as they discuss highlights from his latest book, The Art of Connection: 7 Relationship-Building Skills Every Leader Needs Now. Info: michaelgelb.com. 

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Send us Fan MailIs the era of just managing Parkinson's symptoms finally coming to an end?In this clip from our episode “How AI Is Helping The Fight Against Parkinson's”, host David E. Williams and guest Gene Mack, CEO of Gain Therapeutics, share why the early signals from their lead drug candidate are too compelling to ignore.Listen to the full episode here

Markets gear up for a wave of major earnings this week as trillions in market cap prepare to report. John Belton of Gabelli Funds previews the stakes for markets as earnings season ramps up. Anastasia Amoroso of Partners Group and Bob Elliott of Unlimited debate the outlook for markets, earnings, the Fed and policy risks. Healthcare moves into focus as Angelica Peebles reports on a potential new frontier in heart attack treatment while Goldman's Asad Haider looks ahead to pharma earnings like Lilly and Merck and what investors should expect. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How can we move from fearing equity to championing it?    In this episode of Women of Color Rise, I speak with Celeste Warren, former Vice President and Chief Diversity and Inclusion Officer at Merck and author of The Truth About Equity. With nearly three decades of experience, Celeste has been recognized by Black Enterprise's "Top Executives in Global Diversity and Inclusion."   Celeste's father was the first black teacher and principal in western Pennsylvania. She shares how her "dinner table lessons" taught her that while obstacles are real, they are never an excuse to stop succeeding. She opens up about the internal struggle of stepping into a DEI role as a woman of color and how she learned to stop "putting her blackness to the back." She shares powerful lessons for rising leaders: •The Rocks and the Fence. Equity isn't about taking things away; it's about providing the "rocks" needed to see over systemic fences while we work to tear those fences down. •Boil Your Own Pot. You don't have to save the world alone. Impact starts by influencing the two or three people immediately around you. •Growth vs. Fixed Mindset. View opportunity as a bar graph that can rise infinitely, rather than a finite pie where one person's gain is another's loss. •Embrace Your "Lock and Load" Energy. Learn to balance your drive with a "servant leadership" heart that nurtures and protects your team.   Celeste's journey to global DEI leader is a wonderful model of authenticity and intentionality.   Get full show notes and more information here:https://analizawolf.com/episode-122-build-a-tribe-culture-with-celeste-thompson-founder-of-tribe-consulting

Last December, President Donald Trump convened a meeting of pharmaceutical executives with the goal of getting them to lower the cost of prescription drugs. A few weeks later, one patient battling lung cancer checked into a California clinic for an infusion of Merck & Co.'s blockbuster cancer drug, Keytruda. When the bill arrived, the clinic's charge for a 400 mg dose dominated the page: It was just over $162,000. While Brown only owed about $2,000 herself, the six-figure charges show how quickly prices for cutting-edge medical treatments can balloon in the U.S. health care system. USA TODAY joined the International Consortium of Investigative Journalists in their year-long, reporting effort looking into rising healthcare costs around the world. USA TODAY Health Reporter Ken Alltucker joined The Excerpt to share his insights.Let us know what you think of this episode by sending an email to podcasts@usatoday.com. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.